Af­ter cut­ting back on Vuity last fall, Ab­b­Vie culls a sec­ond-gen pres­by­opia eye drop

In 2021, Ab­b­Vie se­cured the first FDA ap­proval for an eye drop for pres­by­opia, but in 2022 the drug­mak­er re­duced sales and mar­ket­ing on the prod­uct, brand­ed as Vuity. Now, a sec­ond-gen at­tempt at treat­ing the age-re­lat­ed far­sight­ed­ness con­di­tion is go­ing in­to the trash bin.

The Chica­go-area Big Phar­ma up­dat­ed a fed­er­al tri­als data­base late last week to say it had ter­mi­nat­ed a Phase I/II study of AGN-241622. A proof-of-con­cept read­out had been ex­pect­ed in 2023, per a cor­po­rate pre­sen­ta­tion ear­li­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER